NLS type 2 diabetes

Results presented today at the European Association for the Study of Diabetes (EASD) showed that increased awareness about how patients’ and physicians’ perceptions of control differ, could benefit physician-patient communication and improve diabetes management. New findings from the Perceptions of Control (POC) study showed adults with type 2 diabetes uncontrolled on basal insulin had a […]

Egg consumption may reduce the risk of type 2 diabetes, according to new research from the University of Eastern Finland. The findings were published in American Journal of Clinical Nutrition. The dietary habits of 2,332 men aged between 42 and 60 years were assessed at the baseline of the Kuopio Ischaemic Heart Disease Risk Factor […]

Adults with type 2 diabetes treated with Novo Nordisk’s Victoza®, in combination with metformin, experienced similar improvements in blood glucose control while fasting during the four weeks of Ramadan compared with sulfonylurea (SU) plus metformin, according to a recent study.  People treated with Victoza® also demonstrated greater weight loss and fewer confirmed hypoglycemic episodes compared with […]

Novo Nordisk  has successfully completed the phase 2 trial for OG217SC, an oral formulation of the long-acting GLP-1 analogue semaglutidea, a form of oral insulin, sending its stock shares climbing. Semaglutide appeared to have “a safe and well-tolerated profile,” according to Novo Nordisk. The 26-week trial included tests of dose range, escalation, efficacy and safety of once-daily doses […]

Having type 2 diabetes could increase one’s chances of developing Alzheimer’s Disease, according to a study by researchers at Uppsala University in Sweden. The risk comes from amyloid deposits that characterize Alzheimer’s disease forming in the pancreas of type 2 diabetics. Both diseases are characterized by a process called amyloidosis, in which misfolded proteins accumulate into fibrous […]

Novo Nordisk announced that Switzerland is the first country to launch Xultophy® (IDegLira) for people with type 2 diabetes.  Xultophy® is the first combination of a basal insulin [Tresiba® (insulin degludec)] and a GLP-1 analogue [Victoza® (liraglutide)]. Xultophy® is administered as a single injection once a day independently of meals.  It is intended for use in adults with type 2 diabetes who […]